Company Overview

Walpar Nutritions Limited is an India-based nutraceutical, pharmaceutical, and healthcare company incorporated in 2009. The company trades on NSE under the symbol WALPAR and has established itself as a specialized manufacturer in the fast-growing nutraceutical and herbal products segment.

Business Operations and Manufacturing Capabilities

The company is engaged in manufacturing various types of nutraceutical formulations, pharmaceutical ingredients, and pharmaceutical formulations, with vertically integrated Herbo-nutraceutical product manufacturing facilities located in the western parts of India, Gujarat. The company manufactures private label brands for different companies and its own brands, selling through online and direct channels. It manufactures various private label/third-party brands for different companies across the country and overseas.

The company's portfolio includes tablets, capsules, powder/sachets, and oral liquids. It possesses a manufacturing facility in Gandhinagar with an installed manufacturing capacity of 23 lakhs tablet/month, 12.50 lakhs capsules/month, 1.50 lakhs oral liquids/month, and 2 lakhs sachets/month. Walpar Nutritions has developed over 100 formulations and 1000 brands under different segments including Orthopaedics, Cardiac, Diabetic, Dermatology, Pain Management, Antibiotics, Gynaecology, Neuro, Gastro-Intestinal, and sports nutrition.

The product range is extensive, featuring brands like Pcos Care Forte, Procive-F, Procive-M, Proplus, BIOMID, FERROF, FTM-plus, FTW-plus, G-Flora INOSIA-F, Joint-CR, NI-1000, Ortin-5, Ova-Wom, PCOS-CARE, Refitil-F, Refitil-M, Seagut, Spinac, TRIVITA, flaxseed-Oil, Ironica-CR, Magorich, PDF, PIYO, and Ashyuka Plus. The company also operates its own platform for trading of nutraceutical, herbal, ayurvedic, and pharmaceutical raw materials.

Financial Performance and Market Position

As per the latest available data, Walpar Nutritions has reported revenue of ₹71.8 Cr and profit of ₹2.79 Cr. For the half-year ended March 31, 2025, the company reported sales of INR 311.38 million compared to INR 165.2 million a year ago, with revenue of INR 311.98 million compared to INR 165.68 million a year ago, and net income of INR 3.97 million compared to a net loss of INR 3.79 million a year ago.

The company demonstrates solid operational efficiency with reduced debt levels and is almost debt-free. Debtor days have improved from 103 to 71.8 days, and the company's working capital requirements have reduced from 91.3 days to 48.6 days. However, the company has a relatively low return on equity of 5.67% over the last 3 years.

Stock Market Information

Walpar Nutritions Ltd has a market capitalization of ₹44 crore as of February 2025. The promoter holding stands at 68.5%, indicating strong management control and confidence in the business.

Key financial ratios show a stock P/E ratio of 20.2, book value of ₹17.6, and the stock is trading at 2.83 times its book value. The company maintains a dividend yield of 0.00% as it is not currently paying dividends, with ROCE at 16.1% and ROE at 15.1%.

Corporate Structure and Leadership

In the main management, Kalpesh Pravinchandra Ladhawala serves as Chairman and Managing Director, while Priyanka Shah is the Company Secretary. The company was originally formed as a Partnership Firm under the name M/s Walpar Healthcare in November 2009. It was later converted from a Partnership Firm to a Public Limited Company, receiving its Certificate of Incorporation on December 4, 2020.

IPO and Stock Exchange Listing

Walpar Nutritions went public through an IPO that opened on June 30, 2021, and closed on July 5, 2021. Shares were listed on NSE SME on July 13, 2021, at a price of ₹55 per share. The IPO was a SME offering of 1,200,000 equity shares with a face value of ₹10, aggregating up to ₹6.60 Crores.

Recent Corporate Developments

On May 15, 2025, the company announced the approval of audited standalone and consolidated financial results for the financial year ended March 31, 2025, with an unmodified audit opinion. The exchange sought clarification from Walpar Nutritions Limited for the quarter ended March 31, 2025, with respect to Regulation 33 of the SEBI (LODR) Regulations, 2015.

In August 2024, the Board of Directors approved a bonus issue at a ratio of 1:1, with 4,695,220 equity shares for every 4,695,220 equity shares held.

The company operates from its registered office located at 2nd Floor L5:377 Plot No 5 (Omkar Estate), Opp. Sabarmati Gas Station, Village: Khatraj, Taluka: Kalol - 382721 Gandhinagar, Gujarat.

Walpar Nutritions represents a growing player in India's expanding nutraceutical sector, with strong manufacturing capabilities, a diverse product portfolio, and improving financial metrics. The company's focus on contract manufacturing and private labeling positions it well to capitalize on the increasing demand for health and wellness products in both domestic and international markets.